Hemogenyx Pharmaceuticals Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOPHF research report →
Price Chart
About the company
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome.
- CEO
- Vladislav Sandler
- IPO
- 2021
- Employees
- 16
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on HOPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.84M
- P/E
- -4.06
- PEG
- -0.22
- P/S
- 0.00
- P/B
- 10.94
- EV/EBITDA
- -5.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -409.57%
- ROIC
- -155.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-929,890-16.3%
- Op Income
- $-6,980,258
- Net Income
- $-9,760,364-73.7%
- EPS
- $-2.20-3.3%
- OCF Growth
- +16.7%
- FCF Growth
- +16.9%
- 52W High
- $2.33
- 52W Low
- $0.04
- 50D MA
- $2.33
- 200D MA
- $2.33
- Beta
- 1.53
- RSI (14)
- 100
- Avg Volume
- 5.28K
No earnings-call transcripts are available for HOPHF yet.
- Free Float
- 56.3%
- Shares Outstanding
- 6.80M
- Float Shares
- 3.83M
Our HOPHF coverage
Recent articles, reports, and earnings notes.
No research on HOPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HOPHF report →Hemogenyx Pharmaceuticals PLC Announces Notice of AGM
accessnewswire.com · Jun 5
Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term
accessnewswire.com · May 29
Hemogenyx Pharmaceuticals PLC Announces Final Results
accessnewswire.com · Apr 30
Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise
accessnewswire.com · Apr 28
Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA
accessnewswire.com · Apr 14
Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update
accessnewswire.com · Mar 31
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
accessnewswire.com · Feb 27
Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
accessnewswire.com · Feb 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.